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Abstract
Background: Extended follow-up of survivors of ICU treatment has shown many patients suffer
long-term physical and psychological consequences that affect their health-related quality of life.
The current lack of rigorous longitudinal studies means that the true prevalence of these physical
and psychological problems remains undetermined.
Methods/Design:  The ICON (Intensive Care Outcome Network) study is a multi-centre,
longitudinal study of survivors of critical illness. Patients will be recruited prior to hospital discharge
from 20–30 ICUs in the UK and will be assessed at 3, 6, and 12 months following ICU discharge
for health-related quality of life as measured by the Short Form-36 (SF-36) and the EuroQoL (EQ-
5D); anxiety and depression as measured by the Hospital Anxiety and Depression Scale (HADS);
and post traumatic stress disorder (PTSD) symptoms as measured by the PTSD Civilian Checklist
(PCL-C). Postal questionnaires will be used.
Discussion: The ICON study will create a valuable UK database detailing the prevalence of
physical and psychological morbidity experienced by patients as they recover from critical illness.
Knowledge of the prevalence of physical and psychological morbidity in ICU survivors is important
because research to generate models of causality, prognosis and treatment effects is dependent on
accurate determination of prevalence. The results will also inform economic modelling of the long-
term burden of critical illness.
Trial Registration: ISRCTN69112866
Background
Research on the effectiveness of intensive care treatment
has traditionally focused on mortality [1-3]. The cumula-
tive 12 month mortality of survivors of ICU treatment in
the UK varies between 35% and 43% [4,5]. Over the five
years after an ICU admission these patients also have an
excess risk of death when compared to an age and sex
matched population [6]
However, apart from this excess mortality, recent research
has confirmed that survivors of ICU treatment continue to
experience both physical [7], and psychological problems
[4,8,9] for some time after discharge from ICU [7,10]. The
reported prevalence of anxiety and depressive problems in
ICU survivors ranges from 12% to 43% (for anxiety)
[4,11], and 10% to 30% (for depression) [4,11]. Two
recent reviews estimate that 5% to 64% of intensive care
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patients may develop either post traumatic stress disorder
(PTSD) or its associated symptoms that may endure for a
number of years [12,13]. However, the studies reporting
on the rates of PTSD and PTSD symptoms in ICU survi-
vors vary considerably in their case mix, demographic var-
iables, and method and timing of PTSD assessment
[12,13]. All these factors complicate comparisons
between studies and limit quantitative synthesis of their
findings. As a result, the extent to which the consequences
of critical illness or treatments received in the ICU contrib-
ute to the prevalence of PTSD symptoms during recovery
is currently poorly understood. Thus, well-designed stud-
ies are needed to determine accurate prevalence rates of
PTSD in survivors of ICU treatment.
The extended physical and psychological morbidity seen
after critical illness has the potential to affect a patient's
quality of life. Quality of life is determined by several fac-
tors including health status, social relationships, employ-
ment status and the well being of others. Health status
measurements assess physical, physiologic and psycho-
logical states or function, and where these measurements
overlap with components of quality of life is defined as
'Health-Related Quality of Life' (HRQoL) [14]. Studies
assessing HRQoL after intensive care suggest that this
improves over time [15,16], but is worse than before
admission to ICU [16], and worse than general popula-
tion norms [4,15,17]. However, the current literature
assessing HRQoL among ICU survivors [1,3,14,18] has
limitations. First existing UK studies tend to be small and
from single centres. The two largest studies collected data
on only 173 patients 12 months post-discharge [19] and
143 patients 3 months post-discharge [4]. Both these
studies were conducted in single centres. Second, the
existing studies reporting on HRQoL in ICU survivors
have employed a wide number of different outcome
measures, making synthesis of the results impossible.
Third, the majority of the studies lack sufficient rigour.
Heyland et al evaluated 64 studies assessing HRQoL in
ICU survivors (January 1992 – July 1995). Only three
studies (5%) met their pre-set methodological standards
[14]. A major shortcoming was the lack of validation of
the HRQoL measures. Hayes et al reached a similar con-
clusion in their systematic review [1]. The SF-36 and EQ-
5D appear to be the strongest of the existing generic meas-
ures because they have been validated extensively in other
patient populations and are straightforward to administer
[1,3,18]. Both the SF-36 and the EQ-5D also have the
advantage that utilities can be obtained which can be used
to calculate quality-adjusted life years in conjunction with
survival data [3,19,20]. Despite these recommendations
the SF-36 and EQ-5D measures have yet to be used (or
extensively validated) in a large, representative sample of
survivors of adult, general intensive care in the UK [1,3].
Therefore, a UK multicentre study applying these outcome
measures to assess longer-term HRQoL in survivors of
ICU treatment is long overdue.
Aims and objectives of the study
The ICON study aims to:
Define the longer-term outcomes of a large, representative
sample of survivors of adult, general ICU care in the UK
quantitatively in terms of their survival, HRQoL and psy-
chological morbidity 3, 6 and 12 months after ICU dis-
charge.
Compare the mortality of survivors of adult, general ICU
care with age-, sex- and condition-matched populations of
people who have not experienced ICU care.
Methods/Design
This is a multi-centre, longitudinal study.
Ethics Approval
Ethics approval was granted from Oxfordshire Research
Ethics Committee B (Ref:06/Q1605/17).
Participants
Participants meeting the inclusion criteria will be
recruited from 20–30 intensive care units in the UK.
Inclusion criteria
To be eligible for enrolment in the ICON study, partici-
pants must have experienced at least 24 hours of level
three dependency care (ICU) at any time during their hos-
pital stay and who survive until the time of hospital dis-
charge.
Exclusion criteria
Patients will be excluded if they are: aged under 16 years;
unable to complete questionnaires; foreign nationals; in
residential care; unable or unwilling to consent; or if their
life status cannot be traced (i.e. have no GP or NHS num-
bers).
Outcome assessments
Outcomes assessed in the ICON study include mortality,
functional status, HRQoL and psychological outcomes.
Relevant outcomes are assessed at 3, 12 and 24 months
after ICU discharge (Table 1).
Outcomes are assessed with standardised instruments,
most of which are used widely in critical care research.
HRQoL will be measured by the SF-36 [21,24] and the
EQ-5D [22]. The SF-36 is a comprehensive, generic 36-
item questionnaire [26,27] that appears to be an accepta-
ble, reliable and valid tool for use in the ICU population
and its use for quality of life assessment following critical
illness has been recommended [23,15]. The SF-36 con-BMC Health Services Research 2008, 8:132 http://www.biomedcentral.com/1472-6963/8/132
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tains 36 items to measure 8 domains: physical function-
ing, role limitations due to physical problems, bodily
pain, general health perceptions, energy/vitality, social
functioning, role limitations due to emotional problems,
and mental health [21].
The EQ-5D (EuroQoL) has been proved to be a useful tool
in a mixed critical care population [22]. The EQ-5D com-
prises two parts: the EQ-5D self-classifier and the EQ-VAS.
The self-classifier is self-reported description of health
problems according to a 5 dimensional classification i.e.
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression. The EQ-VAS is a self-rated health sta-
tus using a visual analogue scale (VAS). The EQ-VAS is
similar to a thermometer and records perceptions of par-
ticipants own current overall health. The VAS scale is grad-
uated from 0 (the worst imaginable health state) to 100
(the best imaginable state) [24]. Two EQ-VAS will be
included in the three month questionnaire pack. The first
scale one will ask patients to rate their health immediately
prior to their hospital admission that resulted in the ICU
admission. The second scale will be used to rate their
health current health status.
Anxiety and depression will be assessed by the HADS
(Hospital Anxiety and Depression Scale) [25]. The HADS
has been validated in the critical care population
[4,9,11,26]. The HADS questionnaire contains 14 state-
ments and scoring results in scales of 0–21 for anxiety and
depression respectively. Scores of 8–10 indicate the possi-
bility of anxiety or depression, and 11 and above indicate
that these are likely to be present.
PTSD should ideally be diagnosed using consistent crite-
ria and reliable instruments that exhibit high inter-rater
reliability, are stable over time and are able to assess indi-
vidual patients presenting with wide symptom variance
[12]. Currently, the PTSD diagnostic gold standard
remains a structured clinical interview to predefined crite-
ria (e.g. DSM-IV). For obvious reasons, standardised inter-
view is not always practically possible at ICU follow-up,
and the administration of self-report inventories allows
the identification of PTSD symptomatology. The ICON
study will assess PTSD symptomatology using the PTSD
checklist (civilian) (PCL-C). The PCL-C is a 17-item self-
report measure of the 17 DSM-IV symptoms of PTSD
assessing all core symptoms of PTSD i.e. intrusion, avoid-
ance and hyperarousal. It takes minutes to complete and
is a reliable and validated tool with excellent psychomet-
ric properties. A correlation of 0.93 between the total PCL
score and structured interview with the Clinician-Admin-
istered PTSD Scale (CAPS) has been demonstrated (Blan-
chard et al), with a diagnostic efficiency of 0.9 versus the
CAPS. A score of 45 or greater on the PCL-C has been rec-
ommended as a cut off point for high PTSD symptom
load. A total PCL-C cut-off score of 50 has a sensitivity of
0.6 and a specificity of 0.99 of diagnosing PTSD when
compared to Structured Clinical Interview for DSM-IV
[28,29].
In the event of a patient scoring 45 or greater on the PCL-
C and or 11–14 (moderate risk) or 15–21 (severe risk) on
either aspect of the HADS, a standard letter will be sent to
the patient's GP to highlight that they have demonstrated
significant risk of PTSD and or anxiety or depression on
the relevant screening tools. However, the exact inventory
scores will not be given to the GP. If the patient did not
consent for a warning letter to be sent to the GP in the
event of a high inventory score, a standard letter will be
sent to the patient instead. This letter will inform the
patient that their questionnaire results were inconclusive
and they are recommended to visit their GP to discuss
their psychological health.
Procedure
Lists of patients meeting the study inclusion criteria will
be sent from the participating hospitals to the trial office,
which then submits this list to the Office of National Sta-
tistics (ONS). The ONS then performs two checks on the
data. The first check cleans the list to maximise the identi-
fication of individual patients on the ONS databases; the
second check identifies the patients that have died since
hospital discharge. From the list of surviving patients gen-
erated by the ONS, contact with the patient's GP is made
to act as a further check to confirm that the patient is still
alive. Adopting this approach will hopefully prevent a
questionnaire pack being mailed to a deceased patient
and unnecessary distress being caused to their relative.
Table 1: Outcomes assessed at each follow-up point in the Intensive Care Outcome Network (ICON) study
Outcome Instrument(s) Time required a (minutes)
Health-related quality of life SF-36 12
EQ-5D 2
Anxiety and Depression HADS survey 6
PTSD symptoms PCL-C 5
SF-36, Medical Outcomes Study Short Form 36-Item Health Survey; EQ-5D, EuroQOL instrument; HADS, Hospital Anxiety and Depression Scale; 
PCL-C, PTSD Civilian Checklist
a Derived from pilot testingBMC Health Services Research 2008, 8:132 http://www.biomedcentral.com/1472-6963/8/132
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The three-month mailing pack consists of an introductory
letter to the study, a patient information sheet, consent
form, questionnaire set and a FREEPOST envelope. If the
questionnaire pack is not returned, a reminder mailing is
posted four weeks later. Once a patient is enrolled into the
study, they will receive further study packs at 12 and 24
months post ICU discharge as long as they are not subse-
quently identified as deceased by the pre-mailing ONS
check. The 12 and 24 month mailing packs comprise a
reminder letter of the study, the relevant questionnaire
packs and a FREEPOST envelope.
Again, if the patient has not returned either pack 4 weeks
after the initial mailing, a second pack will be sent. If the
questionnaire packs are not returned after the second
mailing, no further attempts will be made to contact the
patient.
Trial recruitment and baseline measurements
All patients discharged from all participating units will be
given a generic discharge letter introducing the study to
them and the possibility that they may receive a mailing
from the ICON study team in the coming months. Data
will be collected on patient demographics, ICU diagnosis,
ICU stay, severity of illness using the Acute Physiology,
and Chronic Health Evaluation (APACHE II) system [30]
and APACHE II co-morbidity score.
Sample size
The minimum target total survivor recruitment for the
study would be at least 1000 survivors per year in the first
year returning all questionnaires. With this sample size,
the ICON study would be the largest existing prospective
cohort study of long-term outcomes in ICU survivors.
Data collection
Participating ICUs will submit monthly lists of patient
names, hospital numbers, CMP numbers, dates of birth,
addresses, and both hospital/ICU admission and dis-
charge dates to the trial office. Just prior to a patient reach-
ing the 3 months post-ICU discharge date, the trial office
will contact the patient's GP to check the patient status on
the relevant patient administration system and ensure eli-
gibility for trial entry. Once it is confirmed that the patient
was successfully discharged from hospital and is still alive,
a three month study pack is mailed. ICNARC (Intensive
Care National Research and Education Centre) will down-
load clinical data to the study office quarterly. Unique
database numbers will link these data with the ICON
database, allowing record linkage studies with ICNARC.
The study office will also snapshot each participating ICU
every six months for staff and unit demographics.
Data protection and PIAG approval
The data collection, storage and access rights will conform
to the standards set out in the Data Protection Act 1998.
In addition, an application will be made to PIAG (Patient
Information Advisory Group) for "Section 60 exemption"
class support to provide a basis in law for holding patient
identifiable data. This is a requirement in UK law (Health
and Social Care Act 2001) for all disease registries.
Although the ICON study needs to hold patient identifia-
ble data to allow checking with the ONS, any second par-
ties wishing to use the data will only have access to
anonymised information.
Data Handling
The data from ICNARC databases, the ONS returns, the
SF-36, EQ-5D, HADS and PCL-C responses will be stored
in a series of linked databases. The data imported as elec-
tronic files (ICU databases and ONS records) will undergo
filtering, validity and range checks before being included.
Data from the paper returns will be scanned and error
checked. The data will be held in off-line storage with two-
tier backup.
Participating units will receive electronic mailings from
the study office giving the number of patients that are cur-
rently being followed-up and the average questionnaire
results of those patients who have consented to take part
in the study.
Planned analyses
Using ICU admission as the event defining the start of fol-
low-up, Kaplan-Meier curves will be constructed to illus-
trate survival. Age and sex matched control data will be
requested from ONS in a 1:1 ratio with the patients in the
study, and a control group Kaplan-Meier curve calculated
from these data. A log-rank test will be used to determine
the statistical significance of any differences noted.
It is almost certain that the ICU survivors will show a
decreased longevity compared with the general popula-
tion, so this initial testing will only be used to validate the
study by showing similar results to previous investiga-
tions. However, as this is a non-randomised study, there
are many potential sources for bias. To minimise the pos-
sibility that a difference in survival is due to confounders
and not a real effect of the either illness or the ICU care,
further covariate analysis will be undertaken. To deter-
mine the effects of covariates on survival, the Cox propor-
tional hazards method will be used. The covariates
included in the model will be age, sex, APACHE II pre-
dicted mortality, socio-economic status (from postcodes),
geographical area (4 zones north to south based on hos-
pital location), month of discharge, and 12 broad diag-
nostic categories based of the organ system involved in the
acute illness. These results will be presented as a tableBMC Health Services Research 2008, 8:132 http://www.biomedcentral.com/1472-6963/8/132
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showing the relative effects of ICU care and the covariates
on survival.
The data on psychological illness (anxiety, depression and
PTSD symptomatology), and quality of life will be largely
descriptive and will be presented in tabular form.
Economic issues
Utility analysis will be performed by estimating Quality
Adjusted Life Years (QALYs) from the survival and EQ-5D
data at 3, 12 and 24 months using standard techniques. A
simple average of QALYs with measures of dispersion will
be calculated. Assuming the data prove to be normally dis-
tributed, standard parametric testing will be used to com-
pare the mean QALYs in ICU survivors with the age and
sex matched controls held in other databases.
Conclusion
The ICON study is a longitudinal study that seeks to pro-
vide rigorous data on the long-term outcome from ICU
treatment in the UK, with a particular emphasis on psy-
chological outcomes. Strengths of the study include com-
prehensive measurement of relevant outcomes and a
relatively large projected sample size. Results from the
ICON study should help inform policy and guide future
research into the care and long-term outcomes of ICU
patients.
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